Thus, to ensure safety during clinical trials, when doxepin is used for the treatment of patients with depression who have an underlying liver disease, regular monitoring of serum ALT and AST levels is essential—even though no formal recommendation for such investigations had been made. This evidence concerns the gene GPT and major depressive disorder.